we were discussing the health situation with jennifer zabasajja.tioned bavarian nordic's involvement on the vaccine front, and we can review those results now for the second quarter. net income coming in at 261.1 million danish krone. the r&d expenses, 209.6 million danish krone. for the four-year it's estimated to be 1.3 5 billion krona. and for the second quarter profit, 420 million. so, a real beat on the estimate of 202.7 million danish krone. so you can see the share price year to date up to 34.4%. over the past seven days. they are expected to benefit even more when it comes to the use of these vaccines. so we keep an eye on bavarian nordic at the open after those results. 8:45 a.m., london time on the opening trade, we will bring you an interview with the ceo on how the mpox vaccine maker is responding to the outbreak. paul chaplin will be speaking to guy johnson and kriti gupta. we have plenty more on daybreak europe coming up for you. so stay with us. this is bloomberg. ♪ lizzy: welcome back to bloomberg daybreak: europe. i just want to ta

our chief africa correspondent, jennifer zabasajja, we thank you.try and impact this situation more as african countries are scrambling to sick her enough inbox -- to secure enough inbox vaccine to deal with the outbreak. we are joined by helen rees of the world health organization. good to have you with me on the program. you are on the ground in johannesburg. what's your read on the scale of the outbreak in the african region and how similar is this to covid? helen: well, i will take your second question first. it is not similar to covid in the sense that covid is airborne. it's a respiratory infection. that makes it very usually spread. you go into an airplane or a room and it's very easy to acquire covid. mpox is spread through contact. we have had mpox in the african region since the 1970's, but the mpox that we saw them was jumping from animal reservoirs, probably small rodents, and households. it was spread in the household and then it would just not spread any further. and that's been going on, particularly in central and west africa, since

jennifer zabasajja joins me for more.e us an update on what we have learned from authorities yesterday. >> you were just pointing to some comments we did get from the africa cdc on tuesday. we did hear from the who, which is trying to dispel concerns that what we're seeing from mpox whether it is a new or old strain, is anything like what we saw with covid and instead trying to stress that we need to avoid the panic before and instead be proactive. you mentioned proactive vaccine distribution which we did hear the africa cdc director talking about how important it is to get africans vaccinated and for that to then help for global health emergency. health officials spending tuesday focusing at least on educating the public on that front. lizzy: which vaccine manufacturers will provide those jabs? >> we have heard a lot of interest from vaccine manufacturers wanting to be part of this global flight. when it comes to testing capabilities, we heard from roche saying they want to update their laboratories to support mpox testi